Literature DB >> 8615423

Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder.

U Halbreich1, F Petty, K Yonkers, G L Kramer, A J Rush, K W Bibi.   

Abstract

OBJECTIVE: Plasma gamma-aminobutyric acid (GABA) levels have been reported to be low in some patients with major depressive disorder. Premenstrual dysphoric disorder is often associated with major depressive disorder. Therefore, the authors sought to determine whether women with premenstrual dysphoric disorder with or without prior major depressive disorder also had low plasma GABA levels.
METHOD: Plasma GABA levels were measured in 27 women with premenstrual dysphoric disorder and 21 comparison women during the the mid-follicular and late luteal phases of the menstrual cycle.
RESULTS: In comparison women, plasma GABA levels increased from the mid-follicular to the late luteal phase. Women with premenstrual dysphoric disorder and a past history of major depressive disorder had low plasma GABA levels during both phases. In women with premenstrual dysphoric disorder but no past major depressive disorder, plasma GABA levels decreased from the nonsymptomatic, mid-follicular phase to the symptomatic, late luteal phase.
CONCLUSIONS: Decreased GABA function may represent a common biological link between subtypes of depressive and premenstrual dysphoric disorders. A trait in major depressive disorder and a state-dependent decrease in premenstrual dysphoric disorder might imply a possible continuum between the two disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615423     DOI: 10.1176/ajp.153.5.718

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  11 in total

1.  Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females.

Authors:  Emily C Bell; Glen B Baker; Christina Poag; Francois Bellavance; Janisse Khudabux; Jean-Michel Le Mellédo
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

Review 2.  The pathophysiologic background for current treatments of premenstrual syndromes.

Authors:  Uriel Halbreich
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 3.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

Review 4.  Disruption of fetal hormonal programming (prenatal stress) implicates shared risk for sex differences in depression and cardiovascular disease.

Authors:  J M Goldstein; R J Handa; S A Tobet
Journal:  Front Neuroendocrinol       Date:  2013-12-16       Impact factor: 8.606

Review 5.  Review article: health benefits of some physiologically active ingredients and their suitability as yoghurt fortifiers.

Authors:  A E Fayed
Journal:  J Food Sci Technol       Date:  2014-05-07       Impact factor: 2.701

Review 6.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

Review 7.  Ovarian steroids and serotonin neural function.

Authors:  C L Bethea; M Pecins-Thompson; W E Schutzer; C Gundlah; Z N Lu
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

8.  Sleep, Hormones, and Circadian Rhythms throughout the Menstrual Cycle in Healthy Women and Women with Premenstrual Dysphoric Disorder.

Authors:  Ari Shechter; Diane B Boivin
Journal:  Int J Endocrinol       Date:  2010-01-18       Impact factor: 3.257

9.  Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression.

Authors:  Kristina M Deligiannidis; Aimee R Kroll-Desrosiers; Shunyan Mo; Hien P Nguyen; Abby Svenson; Nina Jaitly; Janet E Hall; Bruce A Barton; Anthony J Rothschild; Scott A Shaffer
Journal:  Psychoneuroendocrinology       Date:  2016-05-09       Impact factor: 4.905

10.  Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery.

Authors:  A Concas; M C Mostallino; P Porcu; P Follesa; M L Barbaccia; M Trabucchi; R H Purdy; P Grisenti; G Biggio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.